MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/j.1365-2036.2010.04304.x

Медицинская библиотека · Alimentary pharmacology & therapeutics · 2010

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease.

Panaccione R, Colombel J-F, Sandborn W J, Rutgeerts P, D'Haens G R, Robinson A M, Chao J, Mulani P M, Pollack P F

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

In the randomized, double-blind, placebo-controlled CHARM trial, adalimumab was more effective than placebo in maintaining clinical remission for patients with moderate-to-severe Crohn's disease (CD) through 56 weeks.

AIM: To substantiate the long-term safety and clinical benefits of adalimumab through 2 years of therapy in CHARM and its open-label extension (ADHERE).

METHODS

Patients entering ADHERE on blinded therapy received adalimumab 40 mg every other week (eow). Patients who had already moved to open-label adalimumab eow or weekly in CHARM continued their regimens. Data were analysed by originally randomized treatment group at CHARM baseline (adalimumab 40 mg eow, adalimumab 40 mg weekly, or placebo), regardless of whether patients entered ADHERE or received open-label adalimumab (eow or weekly).

RESULTS

After up to 2 years of therapy, 37.6%, 41.9% and 49.8% of patients originally randomized to placebo, adalimumab eow and adalimumab weekly, respectively, were in clinical remission. All groups experienced sustained improvements on the Inflammatory Bowel Disease Questionnaire. Decreasing hazard rates for both all-cause and CD-related hospitalizations were observed over time. Over a 2-year period, the rates of serious adverse events and malignancies (33.3 and 1.1 events/100-patient-years respectively) were similar to those observed during the overall adalimumab CD clinical development programme.

CONCLUSIONS

Adalimumab demonstrated sustained maintenance of clinical remission, improvements in quality of life and reductions in hospitalization during long-term treatment for CD, with no new safety concerns identified.

Для цитирования: Panaccione R, Colombel J-F, Sandborn W J, Rutgeerts P, D'Haens G R, Robinson A M, Chao J, Mulani P M, Pollack P F. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease.. Alimentary pharmacology & therapeutics. 2010. DOI: 10.1111/j.1365-2036.2010.04304.x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.